Showing results (311-320 of 4,238) with videos related to
Sort By:
Pageof 424
Journal for Immunotherapy of Cancer|January 18, 2020
Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality SummitSara Pai, David Blaisdell, Rachel Brodie, et al.Journal for Immunotherapy of Cancer|January 22, 2020
Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor modelsLing Zhang, John S Davies, Carylinda Serna, et al.Journal for Immunotherapy of Cancer|February 6, 2019
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trialHyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, et al.Journal for Immunotherapy of Cancer|February 8, 2019
HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristicsAndressa S Laino, B C Betts, A Veerapathran, et al.Journal for Immunotherapy of Cancer|February 8, 2019
Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor ImmunityJuan J Miret, Paul Kirschmeier, Shohei Koyama, et al.Journal for Immunotherapy of Cancer|January 18, 2019
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trialUlrich Keilholz, Janice M Mehnert, Sebastian Bauer, et al.Journal for Immunotherapy of Cancer|January 18, 2019
Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapyMee Y Bartee, Parker C Dryja, Eric BarteeJournal for Immunotherapy of Cancer|January 9, 2019
Nature of coexisting thyroid autoimmune disease determines success or failure of tumor immunity in thyroid cancerShahnawaz Imam, Pervaiz Dar, Rodis Paparodis, et al.Journal for Immunotherapy of Cancer|December 6, 2018
SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the ArtLisa H Butterfield, Mary L Disis, Bernard A Fox, et al.Journal for Immunotherapy of Cancer|December 6, 2018
Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cellsJiao Wang, Kyle B Lupo, Andrea M Chambers, et al.Pageof 424